Company research
Can-Fite BioPharma Ltd.
CIK 1536196Updated Sep 27, 2026
SecurityCANF · NYSE_AMERICAN · adr
CANF price & chart
Loading TradingView…
AMEX:CANF on TradingView ↗About the company
We are an advanced clinical-stage biopharmaceutical company that develops orally bioavailable small molecule therapeutic products for the treatment of cancer, liver and inflammatory diseases. Our platform technology utilizes the Gi protein associated A3 adenosine receptor, or A3AR, as a therapeutic target. A3AR is highly expressed in pathological body cells such as inflammatory and cancer cells, and has a low expression in normal cells, suggesting that the receptor could be a specific target for pharmacological intervention. Our pipeline of drug candidates are synthetic, highly specific agonists and allosteric modulators targeting the A3AR.
In the news
Wall Street is Watching These Biotechs ↗
Recent filings
Show 5 more recent filings
Financials
FY 2025 · USDSource
Source
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 9,514,000Source | 9,120,000Source | 9,989,000Source | 9,283,000Source |
| Property, Plant and Equipment, NetUSD | 5,000Source | 27,000Source | 29,000Source | 42,000Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 5,528,000Source | 4,825,000Source | 4,278,000Source | 2,978,000Source |
| Accounts Receivable | — | — | — | — |
| Assets, CurrentUSD | 9,440,000Source | 8,982,000Source | 9,908,000Source | 9,157,000Source |
| Prepaid Expense and Other Assets, CurrentUSD | 900,000Source | 1,095,000Source | 986,000Source | 1,170,000Source |
| Operating Lease, Right-of-Use AssetUSD | 69,000Source | 111,000Source | 52,000Source | 84,000Source |
| LIABILITIES AND EQUITY | ||||
| Stockholders’ equity: | ||||
| Additional Paid in CapitalUSD | — | — | 163,597,000Source | 154,192,000Source |
| Retained Earnings (Accumulated Deficit)USD | -176,189,000Source | -166,361,000Source | -158,481,000Source | -150,847,000Source |
| Accumulated Other Comprehensive Income (Loss), Net of TaxUSD | 1,127,000Source | 1,127,000Source | 1,127,000Source | 1,127,000Source |
| Stockholders' Equity Attributable to ParentUSD | 5,592,000Source | 5,436,000Source | 6,243,000Source | 4,472,000Source |
| Additional Paid in Capital, Common StockUSD | 180,654,000Source | 170,670,000Source | — | 500Source |
| Liabilities and EquityUSD | 9,514,000Source | 9,120,000Source | 9,989,000Source | 9,283,000Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | 2,731,000Source | 2,052,000Source | 2,020,000Source | 2,502,000Source |
| Operating Lease, Liability, CurrentUSD | 56,000Source | 53,000Source | 27,000Source | 48,000Source |
| Operating Lease, Liability, NoncurrentUSD | 15,000Source | 51,000Source | 13,000Source | 14,000Source |
| Additional Financial Items | ||||
| Accrued Liabilities, CurrentUSD | — | 301,000Source | — | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 7,882,000Source | 8,903,000Source | — |
| Deferred Revenue, CurrentUSD | — | — | — | 783,000Source |
| Deferred Revenue, NoncurrentUSD | — | — | — | 2,295,000Source |
| Short-term InvestmentsUSD | 1,000Source | 5,000Source | 19,000Source | 8,000Source |
cash flow · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Depreciation, Depletion and AmortizationUSD | 24,000Source | — | — | 14,000Source |
| Share-based Payment Arrangement, Noncash ExpenseUSD | 340,000Source | 362,000Source | 261,000Source | 263,000Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,949,000Source | -7,637,000Source | -8,440,000Source | -10,801,000Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | -2,000Source | 1,495,000Source | 498,000Source | 9,502,000Source |
| Payments to Acquire Property, Plant, and EquipmentUSD | 2,000Source | 5,000Source | 2,000Source | 9,000Source |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 9,644,000Source | 6,711,000Source | 9,144,000Source | — |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash Equivalents, Period Increase (Decrease), Including Exchange Rate EffectUSD | 703,000Source | 547,000Source | 1,300,000Source | -1,412,000Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 5,528,000Source | 4,825,000Source | — | — |
| Effect of Exchange Rate on Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 10,000Source | -22,000Source | 98,000Source | -113,000Source |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 340,000Source | 362,000Source | 261,000Source | — |
| Cash, Cash Equivalents, and Short-term InvestmentsUSD | — | 7,882,000Source | 8,903,000Source | — |
| DepreciationUSD | 24,000Source | 7,000Source | 15,000Source | — |
| General and Administrative ExpenseUSD | 3,662,000Source | 3,047,000Source | 2,955,000Source | 3,143,000Source |
| InterestExpenseNonoperatingUSD | 284,000Source | -291,000Source | — | — |
| Net Income (Loss) Attributable to ParentUSD | -9,828,000Source | -7,880,000Source | -7,634,000Source | -10,173,000Source |
| Nonoperating Income (Expense)USD | 122,000Source | 250,000Source | 561,000Source | -77,000Source |
| Operating ExpensesUSD | 10,355,000Source | 8,804,000Source | — | — |
| Other Nonoperating Income (Expense)USD | — | — | 561,000Source | — |
| Proceeds from Issuance of Common StockUSD | 2,933,000Source | 2,223,000Source | — | — |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 743,000Source | — |
income statement · annual statements
| Line item | FY 2025 | FY 2024 | FY 2023 | FY 2022 |
|---|---|---|---|---|
| Total RevenueUSD | 405,000Source | 674,000Source | — | 810,000Source |
| Selling, General and Administrative ExpenseUSD | — | — | — | 263,000Source |
| Operating Income (Loss)USD | -9,950,000Source | -8,130,000Source | -8,195,000Source | -10,096,000Source |
| Other Nonoperating Income (Expense)USD | — | — | 561,000Source | — |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -9,828,000Source | -7,880,000Source | -7,634,000Source | -10,173,000Source |
| Net Income (Loss) Attributable to ParentUSD | -9,828,000Source | -7,880,000Source | -7,634,000Source | -10,173,000Source |
| Earnings Per Share, BasicUSD per share | -5.97Source | 0Source | -0.01Source | -0.01Source |
| Earnings Per Share, DilutedUSD per share | -5.97Source | 0Source | -0.01Source | -0.01Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 1,646,208Source | 2,175,926,512Source | 1,278,333,912Source | 815,746,293Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 1,646,208Source | 2,175,926,512Source | 1,278,333,912Source | 815,746,293Source |
| Interest Expense (non-operating)USD | 284,000Source | -291,000Source | — | — |
| Additional Financial Items | ||||
| General and Administrative ExpenseUSD | 3,662,000Source | 3,047,000Source | 2,955,000Source | 3,143,000Source |
| Interest Income (Expense), NetUSD | — | — | — | -77,000Source |
| Investment Income, NetUSD | 122,000Source | — | — | — |
| Nonoperating Income (Expense)USD | 122,000Source | 250,000Source | 561,000Source | -77,000Source |
| Operating ExpensesUSD | 10,355,000Source | 8,804,000Source | — | — |
| Other General and Administrative ExpenseUSD | — | — | — | 126,000Source |
| Research and Development ExpenseUSD | 6,693,000Source | 5,757,000Source | 5,983,000Source | 7,763,000Source |
| Revenue from Contract with Customer, Including Assessed TaxUSD | — | — | 743,000Source | — |
Offerings
Registration 333-298625
Registration 333-288890
- Gross proceeds
- 4992916.47
- Net proceeds
- 4642916.48
- Deal price
- 0.6
- Shares
- 8321527
- Offering price
- $0.60
- Ticker
- CANF